title: Waldenström macroglobulinemia.
abstract: Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma. A serum monoclonal IgM protein is required to establish this diagnosis. The clinical features patients develop include normochromic normocytic anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy  and signs of hyperviscosity. The International Staging System for Waldenström macroglobulinemia divides patients prognostically based on age, hemoglobin, platelet count, IgM level, and beta2 microglobulin. Some patients with Waldenström macroglobulinemia have a smoldering form and  can be observed without intervention. Active agents in the treatment of Waldenström macroglobulinemia include rituximab, chlorambucil, cyclophosphamide, fludarabine, bortezomib, lenalidomide, bendamustine, everolimus, and alemtuzumab. The current preferred Mayo Clinic non-study treatment  is rituximab, cyclophosphamide, and dexamethasone. The median survival associated with this disease is now over 10 years.
authors.affiliation: Division of Hematology, Mayo Clinic, 200 First Street, SW, Siebens 667, Rochester, MN 55905, USA. gertz.morie@mayo.edu
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
mesh_terms: D001809:Blood Viscosity; D004358:Drug Therapy; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D011379:Prognosis; D008258:Waldenstrom Macroglobulinemia / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology
chemical_list: D007075:Immunoglobulin M